ReviewCurrent diabetes reports2024
Impact of Remnant Cholesterol on Cardiovascular Risk in Diabetes.
Review in Current diabetes reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Inflammation in atherosclerosis: Drivers, mechanisms and therapies.Acta pharmaceutica Sinica. B · 2026Review
- Risk-weighted apoB: a novel summary metric outperforming traditional lipid biomarkers in predicting coronary heart disease.European heart journal · 2026Article
- Article
- Remnant cholesterol and auditory outcomes in NHANES 1999-2016: associations with frequency-range hearing loss and tinnitus.Lipids in health and disease · 2026Article
- Association of apolipoprotein B and excess apolipoprotein B with cardiovascular risk in type 2 diabetes: a prospective cohort study of the UK Biobank.Lipids in health and disease · 2026Article
- Non-remnant triglyceride-rich lipoproteins due to lipoprotein lipase deficiency increase atherosclerosis in mice.Nature communications · 2026Article
- Remnant cholesterol and lipid ratios predict the relapse of neuromyelitis optica spectrum disorder.Lipids in health and disease · 2026Article
- Remnant cholesterol inflammatory index and mortality in cardiovascular-kidney-metabolic syndrome: a national study.Archives of medical science : AMS · 2026Article
- Association of cumulative remnant cholesterol exposure with adverse outcomes after PCI in acute ST-segment elevation myocardial infarction.Frontiers in cardiovascular medicine · 2026Article
- Comparative Association of Basal and Basal-Prandial Insulin Regimens on Remnant Cholesterol and Lipid Profiles in Patients with Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Triglyceride-glucose index: carotid intima-media thickness and cardiovascular risk in a European population.Cardiovascular diabetology · 2025Article
- Article
- Remnant Cholesterol Inflammatory Index and New-Onset Diabetes in Middle-Aged and Older Adults: Evidence From Prospective Surveys of Chinese and UK Populations.Journal of diabetes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purpose of reviewIndividuals with diabetes face increased risk of atherosclerotic cardiovascular disease (ASCVD), in part due to hyperlipidemia. Even after LDL cholesterol-lowering, residual ASCVD risk persists, part of which may be attributed to elevated remnant cholesterol. We describe the impact of elevated remnant cholesterol on ASCVD risk in diabetes. RECENT
findingsPreclinical, observational, and Mendelian randomization studies robustly suggest that elevated remnant cholesterol causally increases risk of ASCVD, suggesting remnant cholesterol could be a treatment target. However, the results of recent clinical trials of omega-3 fatty acids and fibrates, which lower levels of remnant cholesterol in individuals with diabetes, are conflicting in terms of ASCVD prevention. This is likely partly due to neutral effects of these drugs on the total level of apolipoprotein B(apoB)-containing lipoproteins. Elevated remnant cholesterol remains a likely cause of ASCVD in diabetes. Remnant cholesterol-lowering therapies should also lower apoB levels to reduce risk of ASCVD.
Indexed as
Identifiers
39356419What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.